Quantcast

Latest Biologic Stories

2014-04-03 12:30:06

LONDON, April 3, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Injectable Generic and Biosimilar Drugs - Potential Opportunities for Developers 2013 The market for injectable generics has been through a period of consolidation over the last few years as the leading companies have increased their presence through acquisition. The major players include Hospira, Sandoz (Novartis), Hikma Pharmaceuticals, Fresenius Kabi and Teva Pharmaceutical...

2014-04-03 08:29:54

Novel methodology leverages somatic hypermutation to rapidly generate humanized therapeutic antibodies with >97% human content SAN DIEGO, April 3, 2014 /PRNewswire/ -- AnaptysBio, Inc., a leader in the discovery and development of therapeutic antibodies, announced today that the U.S. Patent and Trademark Office (USPTO) has issued US Patent #8,685,897 broadly covering a novel approach to antibody humanization using somatic hypermutation. Leveraging key advantages of AnaptysBio's...

2014-04-03 08:29:16

DUBLIN, Apr. 03, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/m5wnkh/competitor ) has announced the addition of the "Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in the field of recombinant monoclonal and...

2014-04-03 04:20:52

CAMBRIDGE, England, April 3, 2014 /PRNewswire/ -- GBP19.5M raised to drive development of best-in-class fully human VH antibody fragment therapeutics Crescendo Biologics Limited (Crescendo) today announces it has raised a further GBP2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals GBP19.5m. It was led by Imperial Innovations and included new...

2014-04-02 16:30:36

SEATTLE, and COPHENHAGEN, Denmark, April 2, 2014 /PRNewswire/ -- CMC Biologics, a leading global contract manufacturing organization known for technical excellence and customer satisfaction in biopharmaceutical development and commercial manufacture of protein based therapeutics, was recognized again in 2014 for innovation, quality and reliability by Life Science Leader at an awards ceremony at DCAT Week14 in New York last month....

2014-04-02 12:32:34

NEW YORK, April 2, 2014 /PRNewswire-iReach/ -- A mobile application focusing on rheumatoid arthritis management -- created by DKBmed, LLC, in collaboration with Clifton O. Bingham III, MD, Director of the Johns Hopkins Arthritis Center and the Johns Hopkins University School of Medicine -- was ranked #1 in 2013 by rheumatologists on the Rheumatology Network website and highly rated in 2014 on the Healthline website. Called Rheumatoid Arthritis Vital Education (RAVE) Mobile, the app was...

2014-04-02 08:33:29

BEIJING, April 2, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that the Company has learned that the pending claim in the High Court of Hong Kong (the "Court") against Ms. Siu Ling Chan ("Ms. Chan"), an individual shareholder of the Company, and her spouse, Mr. Tung Lam, had been withdrawn with Court approval. The claim was originally...

2014-04-01 08:27:52

SANTA CLARA, Calif., April 1, 2014 /PRNewswire/ -- ProteinSimple announced today that it has expanded its global direct distribution capabilities by opening an office in Tokyo, Japan. Japan's strong and growing biopharmaceutical business represents a highly attractive market for ProteinSimple's portfolio of innovative protein analysis tools. To support the operation, ProteinSimple has hired Satoshi Ogino, General Manger Japan Sales, to lead a team of experienced sales specialists to...

2014-03-31 08:28:42

-- Conference Call Today, March 31, 2014, at 10:00 a.m. (EDT) -- ROCKVILLE, Md., March 31, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, today reported financial results for the year ended December 31, 2013 and provided operational highlights. http://photos.prnewswire.com/prnvar/20130522/MM19465LOGO Recent Operational Highlights...

2014-03-28 08:26:35

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(®)( )(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.